Breaking News, Financial News

Financial Report: Elan

Elan

2Q Revenues: $136.4 million (+15%)

2Q Loss: $90.5 million (loss of $142.6 million 2Q2005)

YTD Revenues: $270.7 million (+22%)

YTD Loss: $123.8 million (loss of $258.2 million YTD2005)

Comments: The net loss for the quarter was down 37%, primarily due to growth in product revenue and improved operating margins. R&D spending was down 18% to $52.6 million in the quarter. The company launched Tysabri in Germany, Ireland, UK and Sweden and re-introduced it in the U.S. in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters